Radioiodine is important in the diagnostic and therapeutic armamentarium of differentiated
thyroid cancer (DTC); however, many controversies persist. This article addresses some of …

Radioactive iodine therapy has evolved over the past 70 years from treatment of known
metastatic thyroid carcinoma to include adjuvant use to decrease the incidence of recurrent …

Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of
differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear …

Abstract 131 Objective: Radioiodine (I) is considered an e ective and low-risk therapeutic
radionuclide for di erentiated thyroid carcinoma (DTC); however, dilemmas exist in the …

GENERAL aspects of the diagnosis and management of differentiated thyroid carcinoma
(DTC) have been reviewed recently (1) and guidelines for management proposed (2). Yet …

Radioiodine therapy is a matter of controversy because different opinions exist about its use
for differentiated thyroid carcinoma. The following article sheds light on the different opinions …

Thyroid cancer is uncommon, with an incidence of 10,300 new patients each year and a
mortality of 1,100 patients each year. Patient survival correlates with many factors, including …

This article discusses several aspects of the evaluation and management of differentiated
thyroid carcinoma that are changing or may change in the near future. Although …

The first report of patients with thyroid cancer who were treated with radioiodine-131 (131-I)
was in 1946. 1 Since then, radioiodine (RAI) has been an important and wellaccepted …

[en] A large body of evidence indicates that radioiodine (I-131) is of value in the
management or well-differentiated thyroid cancer. These cancers have their origin in thyroid …